Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2999855 | 0.79 | TDP1 (0.43) | POLBPDE10AALDH1A1GAAMDM2 | |
| SCHEMBL14722902 | 0.71 | POLB (0.39) | MAPTPOLBPDE10AALDH1A1NTRK1 | |
| SCHEMBL16815749 | 0.71 | POLB (0.52) | POLBALDH1A1KDM4EMDM2CYP2C9 | |
| SCHEMBL1906019 | 0.71 | POLB (0.52) | MAPTPOLBPDE10AALDH1A1GAA | |
| SCHEMBL5808513 | 0.69 | MAPT (0.55) | MAPTPOLB | |
| SCHEMBL1195389 | 0.69 | TSHR (0.56) | ALDH1A1KDM4EGAA | |
| SCHEMBL7986530 | 0.69 | F2RL1 (0.35) | MAPT | |
| SCHEMBL7986534 | 0.69 | F2RL1 (0.35) | MAPT | |
| SCHEMBL4859521 | 0.68 | POLB (0.48) | POLBALDH1A1MDM2CYP2C9CYP2C18 | |
| SCHEMBL2987627 | 0.68 | POLB (0.48) | POLBALDH1A1MDM2CYP2C9CYP2C18 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174004-B2 | Production method of pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-2748158-B1 | RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-24 | — | — | EP | disclosed |
| EP-2958896-B1 | PRODUCTION METHOD OF PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-30 | — | — | EP | disclosed |
| EP-2602254-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9579407-B2 | Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (PDE10A) in mammals | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-28 | — | — | US | disclosed |
| US-20160002209-A1 | PRODUCTION METHOD OF PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2958896-A1 | PRODUCTION METHOD OF PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2015-12-30 | — | — | EP | disclosed |
| US-9090586-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-28 | — | — | US | disclosed |
| WO-2014129668-A1 | PRODUCTION METHOD OF PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | WO | disclosed |
| EP-2748158-A1 | RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS | Takeda Pharmaceutical Company Limited (JP) | 2014-07-02 | — | — | EP | disclosed |
| US-20140178304-A1 | RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20130150344-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-13 | — | — | US | disclosed |
| EP-2602254-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-06-12 | — | — | EP | disclosed |
| WO-2013027845-A1 | RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178304-A1 | RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS | PDE5A, PDE3B, PDE3A | MAPT 4398/4885POLB 1195/4885PDE10A 5/4885 |
| US-10174004-B2 | Production method of pyridazinone compounds | PNPO, CYP2B6, CYP4B1 | MAPT 2917/4885POLB 565/4885PDE10A 1491/4885 |
| US-20160002209-A1 | PRODUCTION METHOD OF PYRIDAZINONE COMPOUNDS | PNPO, CYP2B6, CYP4B1 | MAPT 2917/4885POLB 565/4885PDE10A 1491/4885 |
| US-20130150344-A1 | HETEROCYCLIC COMPOUND | PDE5A, PDE3A, PDE3B | MAPT 4040/4885POLB 3286/4885PDE10A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.